RBC Capital Rates Natera (NTRA) buy, $275 Price Target
RBC Capital has raised its rating on Natera, Inc. to buy, setting a target price of $275, a 21.72% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
RBC Capital rated Natera, Inc. ($NTRA) "buy" with a $275 price target on June 12, 2026.
Since the rating, $NTRA is up 7.9% after 1 week, up 28.7% after 1 month and up 85.5% to date (from the $212.07 close on Jun 12, 2026).
NTRA
Natera, Inc.
Key Points
- RBC Capital raised its rating on Natera, Inc. (NTRA) to buy on June 12, 2026, with a target price of $275, up from a previous estimate.
- The stock closed at $225.94 on Saturday, which is significantly below the new target, indicating potential upside.
- Analysts remain generally positive on Natera, with a consensus recommendation of strong buy and a mean target price of $348.02.
Get $NTRA trade alerts by text
We text you when insiders, Congress or big funds trade $NTRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
RBC Capital Raises Rating on Natera
RBC Capital has upgraded its rating on Natera, Inc. (NTRA) to buy, with a new price target of $275. This change was announced on June 12, 2026, and reflects a shift in the firm's outlook on the diagnostics company. The stock was priced at $225.94 on Saturday, suggesting a substantial potential for growth based on the new target.
What Changed in RBC Capital's View
This rating adjustment marks a notable change for RBC Capital, which previously had a different stance on Natera. The firm now sees the stock as a buy, indicating it believes the company is positioned for better performance moving forward with a target price significantly above the current market price.
Analysts Set New Price Targets
Natera has received positive feedback from other analysts as well. For instance, JP Morgan maintains an Overweight rating with a target of $460, while Morgan Stanley has also kept an Overweight rating, increasing its target to $435. TD Cowen has a Buy rating with a target of $480, and Barclays maintains an Overweight rating with a target of $475. The average target across all analysts is $348.02, showing a strong consensus on the stock's potential.
Stock Performance Context
The shares of Natera, Inc. have been fluctuating, closing at $225.94 recently. This price is well below its 52-week high of $373.07, indicating that the stock may be undervalued at present. Investors might find the current pricing attractive, especially with the new target suggesting room for significant appreciation.
$NTRA price target
Natera, Inc. daily closes and this analyst's $275 target. Not advice.
What Natera, Inc. Does
Natera, Inc. is a diagnostics company that develops and markets molecular testing services. Its offerings include various cancer tests and prenatal testing solutions. This upgrade from RBC Capital highlights the firm’s growing confidence in Natera’s future prospects, especially as it continues to innovate in the healthcare sector.
Upcoming Earnings
Looking ahead, Natera is set to report its next earnings on November 5, 2026. Investors will be keen to see how the company performs and whether it can meet the expectations set by analysts following the recent upgrades. As a reminder, the adjustments in ratings and targets reflect analysts' views as of the reporting period and may not represent current positions.
Related Filing Alerts
Source: RBC Capital's rating change on $NTRA (Jun 12, 2026). Written by software, not financial advice. How we make alerts